← SynDRA
ROSIGLITAZONE
SynDRA canonical compound SYN0001042 — structure-anchored drug synonym record
| Clinical phase | Withdrawn |
|---|
| Approval status | Approved · OTC |
|---|
| Primary target(s) | PPARG |
|---|
| Mechanism of action | PPAR receptor agonist |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | Insulin sensitizer |
|---|
All known targets
- PPARG
- TRPC5
- FFAR1
- TRPM3
- Maob
- TBXAS1
- SLC10A1
- RXRA
- RARG
- Pparg
- Ppara
- PPARD
Mechanisms of action (all sources)
- Insulin sensitizer
- PPAR receptor agonist
- PPARG AGONIST
- Peroxisome proliferator-activated receptor gamma agonist
- FFAR1 FULL AGONIST
- PPARG FULL AGONIST
- TRPC5 ACTIVATOR
- TRPM3 MODULATOR
- insulin sensitizer, ppar receptor agonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- RARA
- ADRA2A
- NR1I2
- CRHR2
- HTR2A
- NR1H2
- MLNR
- MMP1
- MMP9
- NFE2L2
- NPY1R
- NPY2R
- NR1H3
- MC4R
- NR1H4
- HSD17B10
- NR1I3
- NR2C1
- NR2E1
- NR3C1
- MC5R
- MC3R
- HTR2B
- KDM4A
- HTR2C
- HTR3A
- HTR1A
- HTR6
- HTR7
- KDM1A
- KDM4E
- MAPK3
- KEAP1
- LCK
- LMNA
- MAPK1
- MAPK14
- NR4A1
- ABCC2
- NR5A1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ACM1
- MPC2
- TRFR
- SYK
- PRGR
- PHGDH
- NF2L2
- NCOA2
- MPC1
- CP2C9
- KSYK
- KCMB1
- HDAC9
- CRHBP
- CP3A7
- CP2D6
- TRHR
Drug classes
- Peroxisome Proliferator-activated Receptor Activity
- Peroxisome Proliferator-activated Receptor gamma Agonists
- Hypoglycemic Agents
- Peroxisome Proliferator Receptor gamma Agonist
- Thiazolidinedione
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- AVANDAMET
- AVANDARYL
- AVANDIA
- ROSIGLITAZONE MALEATE
- ROSIGLITAZONE MALEATE AND GLIMEPIRIDE
- ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE
- rosiglitazone maleate
- rosiglizole
- rosiglitazone hydrochloride
- rosiglitazone HCl
- Rosiglitazona
- Avandamet
- Avandaryl
- Gaudil
- Rezult
- Rosiglizole
- Rosvel
- BRL-49653
- NSC-758698
- TDZ-01
- Avandia
- Nyracta
- Venvia
- Rosiglitazone XR
- Rosiglitazone Maleate [USAN]
- Rosiglitazone maleate
- BRL-49653C
- Avandia (TN)
- Avandiaadministration for 6-12 weeks
- BRL 49653-C
- SB-206846
- SB-210232
- Rosiglitazone maleate (JAN/USAN)
- TDZ 01
- NSC 758698
- Brl 49653
- rosiglitazone (iarc)
- rosiglitazona
Reported adverse events
- Lactic acid
- Lactic acidosis
- Arthralgia
- Back pain
- Fatigue
- Headache
- Hypertension
- Injury
- Nasopharyngitis
- Sinusitis
- Stevens-Johnson syndrome
- Upper respiratory tract infection
Look up ROSIGLITAZONE in the interactive SynDRA portal →